ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jones, A.M.
Right arrow Articles by Webb, A.K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, A.M.
Right arrow Articles by Webb, A.K.
Eur Respir J 2003; 22:503-506
Copyright ©ERS Journals Ltd 2003

Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa

A.M. Jones1, L. Martin2, R.J. Bright-Thomas1, M.E. Dodd1, A McDowell2, K.L. Moffitt2, J.S. Elborn3 and A.K. Webb1

1 Manchester Adult Cystic Fibrosis Centre, South Manchester University Hospitals NHS Trust, Manchester, 2 School of Pharmacy, Queen's University, Belfast, and 3 Northern Ireland Adult Cystic Fibrosis Centre, Belfast City Hospital, Belfast, UK

CORRESPONDENCE: A.M. Jones, Manchester Adult Cystic Fibrosis Centre, South Manchester University Hospitals NHS Trust, Southmoor Road, Manchester, M23 9LT, UK. Fax: 44 1612912080. E-mail: andmarkj@hotmail.com

Keywords: cross-infection, cystic fibrosis, inflammation, Pseudomonas aeruginosa

Received: January 14, 2003
Accepted May 8, 2003


   Abstract
TOP
 Abstract
Methods
 Results
 Discussion
 Acknowledgements
 References
 
Chronic Pseudomonas aeruginosa infection in cystic fibrosis (CF) leads to a damaging host inflammatory response. There are an increasing number of reports of P. aeruginosa cross-infection at CF centres. The clinical significance of acquisition of a transmissible strain for patients who already harbour P. aeruginosa is unclear. In this study, levels of inflammatory markers in clinically stable adult CF patients who harbour transmissible and sporadic strains of P. aeruginosa have been compared.

Patients with CF and chronic P. aeruginosa infection were grouped into those who harbour a transmissible P. aeruginosa and those who harbour their own sporadic strains. Total white cell and differential counts, sputum neutrophil elastase (NE), interleukin (IL)-8, tumour necrosis factor (TNF)-{alpha}, plasma IL-6 and NE/{alpha}1-antitrypsin complexes, serum C-reactive protein, and urine TNF receptor 1 were all measured in clinically stable patients 4–6 weeks following completion of intravenous antibiotic therapy.

The two groups (both n=20) were well matched for per cent predicted forced expiratory volume in one second, per cent predicted forced vital capacity and body mass index. There were no significant differences in levels of white cell counts or inflammatory markers between the two groups.

At times of clinical stability, cystic fibrosis patients infected with transmissible Pseudomonas aeruginosa do not have a heightened inflammatory response above that of those harbouring sporadic strains.

The major cause of morbidity and mortality for individuals with cystic fibrosis (CF) is pulmonary disease due tochronic infection and a damaging host inflammatory response. The major bacterial pathogen involved is Pseudomonas aeruginosa 1. Recently, there have been a number of reports of P. aeruginosa cross-infection outbreaks at CF centres and holiday camps 2–8. Isolates of many of the transmissible strains commonly exhibit unusual phenotypic features; morphotypes of the most prevalent transmissible strain at the Manchester Adult CF Centre, P. aeruginosa strain MA, are associated with an unusual pyocin type, are nonpigmented, nonmotile and are often resistant to the majority of usual anti-pseudomonal antibiotics 3. The clinical significance of acquisition of a transmissible strain for patients who already harbour their own sporadic strain ofP. aeruginosa is unclear, although some clinicians have reported an increase in morbidity 2, 8, 9 and mortality 2 among CF patients infected with a transmissible strain of P.aeruginosa.

Airway inflammation is a major factor in the pathogenesis of CF lung disease. Inflammatory mediators as markers of the host response to infection may reflect the intensity of lung injury and relate to changes in clinical status. When clinically stable, CF patients with chronic P. aeruginosa infection are known to have increased levels of inflammatory markers compared to the non-CF population 10, 11. If transmissible strains of P. aeruginosa are more virulent they may provoke an enhanced inflammatory response. In this study, levels ofinflammatory markers in clinically stable adult CF patientswho harbour a transmissible P. aeruginosa have been compared with those harbouring sporadic strains of P.aeruginosa.


   Methods
TOP
 Abstract
 Methods
Results
 Discussion
 Acknowledgements
 References
 
CF patients with chronic P. aeruginosa infection who attend the Manchester Adult CF Centre were invited to participate in the study if they were clinically stable (defined as an absence of new symptoms and stable pulmonary function) and had received a course of i.v. antibiotic treatment 4–6 weeks earlier. The course of i.v. antibiotic treatment was of at least 7 days duration and consisted of a combination of at least two different classes of intravenous anti-pseudomonal antibiotics. The in vitro sensitivity of the P.aeruginosa from the most recently available sputum isolate is used to guide antibiotic choice and adjusted where appropriate when a current culture is available. Approval for the study was given by South Manchester Research Ethics Committee and written informed consent was obtained from each patient.

Patients were grouped on the basis of results of prospective bacterial fingerprinting of P. aeruginosa isolates from sputa, as previously reported 3. Patients were grouped into those who have harboured a transmissible strain of P. aeruginosa (P. aeruginosa strain MA) for at ≥12 months and those whoharbour their own sporadic P. aeruginosa. The two groups were prospectively matched by per cent predicted forced expiratory volume in one second (%FEV1). Patients co-infected with Burkholderia cepacia complex or other transmissible strains of P. aeruginosa were excluded from the study. Baseline patient demographics in the study were age, sex, CF genotype, presence of pancreatic insufficiency and/or diabetes mellitus, and use of nebulised antibiotics, deoxyribonuclease, long-term oral macrolide antibiotics, inhaled corticosteroids, and oral corticosteroids. %FEV1, per cent predicted forced vital capacity (%FVC) and body mass index (BMI) were measured. The total duration of the previous course of i.v. antibiotics and time from completion to the study visit were recorded. The in vitro phenotypic appearance (nonmucoid or mucoid) and antibiotic sensitivity patterns of the P. aeruginosa isolates were noted. For thepurpose of this study, multiresistance was defined as resistance to two of the three major classes of usual antipseudomonal antibiotics (aminoglycosides, quinolones, ß-lactams). Antibiotic resistance was assessed by the British Society for Antimicrobial Chemotherapy standardised disc testing method. Susceptibility and resistance of isolates was based on standard breakpoint values for each antibiotic (British Society for Antimicrobial Chemotherapy).

A sample of whole blood was analysed the same day for total white cell and differential cell counts. Samples of sputum, urine, plasma and serum were obtained for measurement of inflammatory markers. Sputum was diluted weight for weight with 0.9% (weight/volume) saline in a 1:5 ratio, centrifuged at 3000xg for 30 min and the supernatant collected. All samples were stored in aliquots at –80°C pending the measurement of inflammatory mediators.

Inflammatory markers were analysed as a single batch byablinded investigator. The levels of the following markerswere measured: sputum neutrophil elastase (NE), interleukin (IL)-8 and tumour necrosis factor (TNF)-{alpha}, plasma IL-6 andNE/{alpha}1-antitrypsin complexes, serum C-reactive protein (CRP), and urine TNF receptor 1. NE was detected by spectrophotometric assay, utilising the substrate N-Methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide. All other parameters were measured by commercially available enzyme-linked immunosorbent assays (ELISA), with the exception ofNE/{alpha}1-antitrypsin complexes, which were detected byan ELISA developed within the authors' laboratory, andrelevant performance and quality control checks were conducted.

Statistical analysis
The baseline demographics of the two groups were compared by Chi-squared and unpaired t-tests. The differences in total white cell and neutrophil counts were analysed using a two-sample t-test. Group differences in levels of inflammatory markers were assessed by the Mann-Whitney U-test.


   Results
TOP
 Abstract
 Methods
 Results
Discussion
 Acknowledgements
 References
 
For the transmissible group there were 22 eligible patients (i.e. patients who had chronic infection with the transmissible P. aeruginosa strain MA for >12 months); 20 out of 22 patients were recruited. Two were not recruited, as they did not receive a course of i.v. antibiotics over the study period. The 20 patients with the transmissible strain were matched by %FEV1 with 20 CF patients harbouring sporadic P. aeruginosa. The two groups (sporadic versus transmissible P.aeruginosa strains) were well matched in terms of mean age, %FEV1, %FVC, BMI and demographic features (table 1Go). Patients received i.v. antibiotic therapy for a median (range) of 14 (9–37) and 14 (8–28) days (p=0.68) in the sporadic and transmissible P. aeruginosa groups, respectively. The study visit was a mean (se) 35.8 (1.2) and 33.7 (0.9) days (p=0.20) after the final day of i.v. antibiotic treatment for the sporadic and transmissible P. aeruginosa groups, respectively. There were no differences between the sporadic and transmissible P.aeruginosa groups in median change in %FEV1 (–2.2 (–11.5–15.4) and –2.5 (–23.5–6.3); p=0.57), %FVC (–3.9 (–14.1–6.6) and –5.0 (–50.7–6.4); p=0.37) or BMI (0.15 (1.2––1.3) and 0.15 (–0.8–1.2); p=0.36) from the end of the course of i.v. antibiotics to the study day.


View this table:
[in this window]
[in a new window]
  		Table 1 Demographics of cystic fibrosis (CF) groups

 
Whole blood, plasma and serum samples were obtained from all patients. Two patients in the transmissible P. aeruginosa group were unable to produce a sputum sample. Two patients in the sporadic P. aeruginosa group were unable to produce a urine sample because of time restraints on the study day. The results of whole blood white cell and neutrophil counts and the levels of inflammatory markers are given in table 2Go. There was no difference between the twogroups for the levels of white cell counts and the inflammatory markers.


View this table:
[in this window]
[in a new window]
  		Table 2 White cell counts (WCC) and inflammatory markers in cystic fibrosis patients with chronic Pseudomonas aeruginosa (P. aeruginosa) infection

 

   Discussion
TOP
 Abstract
 Methods
 Results
 Discussion
Acknowledgements
 References
 
This study examines differences in levels of inflammatory markers between two groups of clinically stable CF patients with chronic P. aeruginosa infection; those who harbour their own sporadic P. aeruginosa and those who harbour a transmissible strain (P. aeruginosa strain MA). There were no differences in levels of inflammatory markers between thetwo groups.

There are an increasing number of reports of P. aeruginosa cross-infection outbreaks among individuals with CF 2–7, 12. The significance of P. aeruginosa cross-infection and the provision of resources for microbiological surveillance and implementation of infection control measures remains controversial 13–16. Whilst new acquisition of P. aeruginosa bypreviously "Pseudomonas-naïve" CF patients is associated with a worsening of their clinical status 1, 17–21, the effect ofacquisition of a different strain for patients who already harbour P. aeruginosa is unclear. However, there are reasons for CF physicians to be concerned about transmissible strains of P. aeruginosa. Isolates belonging to transmissible strains of P. aeruginosa often exhibit unusual phenotypic characteristics 3, including in vitro antibiotic resistance 2, 3, 6. In the present study, a higher number (16 out of 20) of patients in the transmissible P. aeruginosa group were found to harbour a multi-resistant P. aeruginosa isolate than patients with sporadic strains (three out of 20) (p<0.001). Transmissible strains have also been associated with super-infection of CF patients who already harbour other P. aeruginosa 4. The authors have previously documented an increase in treatment requirements for adult CF patients who harbour a transmissible strain of P. aeruginosa 9. More worrying is a report from Nixon et al. 2 of an increased morbidity and mortality for CF children in association with P. aeruginosa cross-infection. A recent publication by Armstrong et al. 8 observed a lower %FEV1 among patients at a paediatric CF centre who harboured a transmissible P. aeruginosa; however, the two groups were not prospectively matched.

There is a current lack of published data as to whether transmissible P. aeruginosa are more virulent than sporadic strains, but such information is needed by CF clinicians. The current study was designed to investigate whether adult CF patients who harbour transmissible P. aeruginosa strain MA demonstrate a more florid host inflammatory response than those who harbour sporadic strains of P. aeruginosa. Patients with chronic P. aeruginosa infection experience episodes of respiratory exacerbations that are associated with a decrease in lung function and a systemic inflammatory response, with increased levels of inflammatory markers, including TNF-{alpha}, NE/{alpha}1-antitrypsin complexes, IL-6, IL-8 and CRP 11, 22–24. I.v. antibiotic therapy leads to a reduction in host inflammatory responses 11, 23. However, even at times of apparent clinical stability, CF patients with chronic P. aeruginosa infection still demonstrate increased levels of inflammatory markers indicating chronic inflammatory activity and accompanying lung injury 11, 24–26. The persistent inflammatory response to chronic pulmonary infection also leads to an increased resting energy expenditure and patient metabolism 23, adversely affecting nutritional status. If some strains of P. aeruginosa are more virulent they should be more likely to provoke an enhanced host inflammatory response. However, in this study, no differences in levels of inflammatory markers were shown between CF patients with infection by transmissible and sporadic strains of P. aeruginosa at times of clinical stability.

Although these findings provide a degree of reassurance forclinicians that care for CF patients who harbour transmissible P. aeruginosa, the study has a number of drawbacks. First, as the number of CF patients identified as harbouring transmissible P. aeruginosa is small, subjects for such studies are limited and it is, therefore, difficult to fully exclude a type-2 error. Secondly, some patients who harbour the transmissible strain are co-infected with a sporadic P. aeruginosa strain. However, although inclusion of these patients might bias results, particularly if a transmissible strain was less virulent, these subjects make the group more representative ofthe CFpatients in clinical practice. Thirdly, in addition tobacterial virulence factors, DNA polymorphisms in host genes regulating inflammatory responses to respiratory pathogens may influence levels of inflammatory markers 27. It is difficult both to assess and make allowances for such a potential confounding variable in an in-vivo study. Finally, measuring levels of host inflammatory markers may not provide an accurate prediction of future clinical outcome. A previous study did not find a difference in levels of blood cytokines between CF patients with P. aeruginosa and B. cepacia complex 22, despite a well-recognised increased pathogenicity of B. cepacia complex in clinical practice 28,29. However, that study had smaller numbers of subjects andmeasured circulating inflammatory markers, which may not be as representative of inflammatory activity within the lung as those in bronchoalveolar lavage fluid or sputa. The present study recruited a greater number of patients andexamined inflammatory markers in sputa and the circulation.

In conclusion, at times of clinical stability, cystic fibrosis patients infected with transmissible Pseudomonas aeruginosa do not have a heightened inflammatory response above those who harbour sporadic strains. Further prospective studies are needed to assess the long-term clinical effects of spread of transmissible Pseudomonas aeruginosa strains among individuals with cystic fibrosis.


   Acknowledgements
TOP
 Abstract
 Methods
 Results
 Discussion
 Acknowledgements
References
 
The authors would like to gratefully acknowledge the assistance of J.R.W. Govan, C.J. Doherty and the staff of Medical Microbiology, University of Edinburgh, UK, in typing of the P. aeruginosa isolates.


   References
TOP
 Abstract
 Methods
 Results
 Discussion
 Acknowledgements
 References
 

  1. Cystic Fibrosis Foundation. Patient registry 1999 annual reportBethesda, MA, Cystic Fibrosis Foundation, 2000.
  2. Nixon GM, Armstrong DS, Carzino R, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001;138:699–704.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  3. Jones AM, Govan JR, Doherty CJ, et al. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet 2001;358:557–558.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  4. McCallum SJ, Corkill J, Gallagher M, Ledson MJ, Hart CA, Walshaw MJ. Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P. aeruginosa. Lancet 2001;358:558–560.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  5. Ojeniyi B, Frederiksen B, Hoiby N. Pseudomonas aeruginosa cross-infection among patients with cystic fibrosis during a winter camp. Pediatr Pulmonol 2000;29:177–181.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  6. Cheng K, Smyth RL, Govan JR, et al. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996;348:639–642.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  7. Hunfeld KP, Schmidt C, Krackhardt B, et al. Risk of Pseudomonas aeruginosa cross-colonisation in patients with cystic fibrosis within a holiday camp – a molecular-epidemiological study. Wien Klin Wochenschr 2000;112:329–333.[ISI][Medline] [Order article via Infotrieve]
  8. Armstrong DS, Nixon GM, Carzino R, et al. Detection of a widespread clone of Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic. Am J Respir Crit Care Med 2002;166:983–987.[Abstract/Free Full Text]
  9. Jones AM, Dodd ME, Doherty CJ, Govan JRW, Webb AK. Increased treatment requirements of patients with cystic fibrosis who harbour a highly transmissible strain of Pseudomonas aeruginosa. Thorax 2002;57:924–925.[Abstract/Free Full Text]
  10. Bonfield TL, Panuska JR, Konstan MW, et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995;152:2111–2118.[Abstract]
  11. Nixon LS, Yung B, Bell SC, Elborn JS, Shale DJ. Circulating immunoreactive interleukin-6 in cystic fibrosis. Am J Respir Crit Care Med 1998;157:1764–1769.
  12. Pedersen SS, Koch C, Hoiby N, Rosendal K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother 1986;17:505–516.[Abstract/Free Full Text]
  13. Hoogkamp-Korstanje JA, Meis JF, Kissing J, van der Laag J, Melchers WJ. Risk of cross-colonization and infection by Pseudomonas aeruginosa in a holiday camp for cystic fibrosis patients. J Clin Microbiol 1995;33:572–575.[Abstract]
  14. Geddes DM. Of isolates and isolation: Pseudomonas aeruginosa in adults with cystic fibrosis. Lancet 2001;358:522–523.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  15. Pitt TL. Cross infection of cystic fibrosis patients with Pseudomonas aeruginosa. Thorax 2002;57:921.[Free Full Text]
  16. Ramsay BW. To cohort or not to cohort: how transmissible is Pseudomonas aeruginosa?. Am J Respir Crit Care Med 2002;166:906–907.[Free Full Text]
  17. Hudson VL, Wielinski CL, Regelmann WE. Prognostic implications of initial oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two years. J Pediatr 1993;122:854–860.[ISI][Medline] [Order article via Infotrieve]
  18. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;23:330–335.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  19. Kosorok MR, Zeng L, West SE, et al. Acceleration of lungdisease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001;32:277–287.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  20. Kerem E, Corey M, Gold R, Levison H. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr 1990;116:714–719.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  21. Pamukcu A, Bush A, Buchdahl R. Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr Pulmonol 1995;19:10–15.[ISI][Medline] [Order article via Infotrieve]
  22. Hendry J, Elborn JS, Nixon L, Shale DJ, Webb AK. Cystic fibrosis: inflammatory response to infection with Burkholderia cepacia and Pseudomonas aeruginosa. Eur Respir J 1999;14:435–438.[Abstract]
  23. Bell SC, Bowerman AM, Nixon LE, Macdonald IA, Elborn JS, Shale DJ. Metabolic and inflammatory responses to pulmonary exacerbation in adults with cystic fibrosis. Eur J Clin Invest 2000;30:553–559.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  24. Elborn JS, Cordon SM, Parker D, Delamere FM, Shale DJ. The host inflammatory response prior to death in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection. Respir Med 1993;87:603–607.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  25. Brown MA, Morgan WJ, Finley PR, Scuderi P. Circulating levels of tumor necrosis factor and interleukin-1 in cystic fibrosis. Pediatr Pulmonol 1991;10:86–91.[ISI][Medline] [Order article via Infotrieve]
  26. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992;12:158–161.[ISI][Medline] [Order article via Infotrieve]
  27. Hull J, Thomson AH. Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis. Thorax 1998;53:1018–1021.[Abstract/Free Full Text]
  28. Jones AM, Dodd ME, Webb AK. Burkholderia cepacia: current clinical issues, environmental controversies and ethical dilemmas. Eur Respir J 2001;17:295–301.[Abstract/Free Full Text]
  29. Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970–1989. Am J Epidemiol 1996;143:1007–1017.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Chronic Respiratory DiseaseHome page
J S Elborn
Practical Management of Cystic Fibrosis
Chronic Respiratory Disease, July 1, 2006; 3(3): 161 - 165.
[PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
B. P. O'Sullivan and A. D. Michelson
The Inflammatory Role of Platelets in Cystic Fibrosis
Am. J. Respir. Crit. Care Med., March 1, 2006; 173(5): 483 - 490.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
D. Chambers, F. Scott, R. Bangur, R. Davies, A. Lim, S. Walters, G. Smith, T. Pitt, D. Stableforth, and D. Honeybourne
Factors associated with infection by Pseudomonas aeruginosa in adult cystic fibrosis
Eur. Respir. J., October 1, 2005; 26(4): 651 - 656.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
K.W. Southern and P.M. Barker
Azithromycin for cystic fibrosis
Eur. Respir. J., November 1, 2004; 24(5): 834 - 838.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
D.W. Reid, A. Champion, R. Bradbury, and S.M. Kirov
Host response to transmissible Pseudomonas aeruginosa
Eur. Respir. J., March 1, 2004; 23(3): 493 - 494.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jones, A.M.
Right arrow Articles by Webb, A.K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, A.M.
Right arrow Articles by Webb, A.K.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS